45 results
Keyword Everolimus Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Afinitor
everolimus, Carcinoma, Renal Cell Breast Neoplasms Pancreatic Neoplasms
Date of authorisation: 02/08/2009, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Votubia
everolimus, Tuberous Sclerosis
Date of authorisation: 01/09/2011, Revision: 24, Authorised -
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib, Carcinoma, Renal Cell
Date of authorisation: 24/08/2016, Additional monitoring, Revision: 6, Authorised -
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib, Carcinoma, Renal Cell
Date of authorisation: 08/09/2016, Additional monitoring, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Opdivo (updated)
nivolumab, Melanoma Hodgkin Disease Carcinoma, Renal Cell Carcinoma, Non-Small-Cell Lung
Date of authorisation: 18/06/2015, Additional monitoring, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Voriconazole Accord
voriconazole, Aspergillosis Candidiasis Mycoses
Date of authorisation: 16/05/2013, Generic, Revision: 9, Authorised -
List item
Human medicine European public assessment report (EPAR): Darunavir Mylan
darunavir, HIV Infections
Date of authorisation: 03/01/2017, Generic, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Darunavir Krka d.d.
darunavir, HIV Infections
Date of authorisation: 17/01/2018, Generic, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Darunavir Krka
darunavir, HIV Infections
Date of authorisation: 25/01/2018, Generic, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira)
voriconazole, Bacterial Infections and Mycoses Aspergillosis Candidiasis
Date of authorisation: 27/05/2015, Generic, Revision: 4, Authorised -
List item
Human medicine European public assessment report (EPAR): Ranexa (previously Latixa)
ranolazine, Angina Pectoris
Date of authorisation: 08/07/2008, Revision: 15, Authorised -
List item
Human medicine European public assessment report (EPAR): Viekirax
ombitasvir / paritaprevir / ritonavir, Hepatitis C, Chronic
Date of authorisation: 14/01/2015, Additional monitoring, Revision: 15, Authorised -
List item
Human medicine European public assessment report (EPAR): Emend
aprepitant, Vomiting Postoperative Nausea and Vomiting Cancer
Date of authorisation: 10/11/2003, Revision: 24, Authorised -
List item
Human medicine European public assessment report (EPAR): Lutathera
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017, Additional monitoring, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Prezista
darunavir, HIV Infections
Date of authorisation: 11/02/2007, Revision: 43, Authorised -
List item
Human medicine European public assessment report (EPAR): Ritonavir Mylan
ritonavir, HIV Infections
Date of authorisation: 09/11/2017, Generic, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Norvir
ritonavir, HIV Infections
Date of authorisation: 25/08/1996, Revision: 59, Authorised -
List item
Human medicine European public assessment report (EPAR): Ibrance
palbociclib, Breast Neoplasms
Date of authorisation: 08/11/2016, Additional monitoring, Revision: 5, Authorised -
List item
Human medicine European public assessment report (EPAR): Inlyta
axitinib, Carcinoma, Renal Cell
Date of authorisation: 02/09/2012, Revision: 8, Authorised -
List item
Human medicine European public assessment report (EPAR): Rezolsta
darunavir / cobicistat, HIV Infections
Date of authorisation: 19/11/2014, Additional monitoring, Revision: 6, Authorised -
List item
Human medicine European public assessment report (EPAR): Faslodex
fulvestrant, Breast Neoplasms
Date of authorisation: 09/03/2004, Revision: 19, Authorised -
List item
Human medicine European public assessment report (EPAR): Ivemend
fosaprepitant, Vomiting Cancer
Date of authorisation: 10/01/2008, Revision: 20, Authorised -
List item
Human medicine European public assessment report (EPAR): Votrient
pazopanib, Carcinoma, Renal Cell
Date of authorisation: 13/06/2010, Revision: 20, Authorised -
List item
Human medicine European public assessment report (EPAR): Symtuza
darunavir / cobicistat / emtricitabine / tenofovir alafenamide, HIV Infections
Date of authorisation: 20/09/2017, Additional monitoring, Revision: 5, Authorised -
List item
Human medicine European public assessment report (EPAR): Kisqali
ribociclib, Breast Neoplasms
Date of authorisation: 21/08/2017, Additional monitoring, Revision: 0, Authorised